Glycerol trioleate/glyeerol trierueate therapy in X-linked adrenoleukodystrophy: Saturated and unsaturated fatty acids in blood cells. Implications for the follow-up

Journal of Inherited Metabolic Disease

Volumn 19, Issue 2, 1996, Pages 188-192

  Ruiz, M ^a   Pampols, T ^a   Giros M ^a  

^a Institut de Bioquimica Clinica Barcelona   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ERUCIC ACID; SATURATED FATTY ACID; TRIOLEIN; UNSATURATED FATTY ACID; VERY LONG CHAIN FATTY ACID;

ADRENOLEUKODYSTROPHY; BIOACCUMULATION; BLOOD CELL; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN CELL; MALE; MONONUCLEAR CELL; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADRENOLEUKODYSTROPHY; ERUCIC ACIDS; FATTY ACIDS; FATTY ACIDS, UNSATURATED; HUMANS; LEUKOCYTES, MONONUCLEAR; LINKAGE (GENETICS); TRIGLYCERIDES; TRIOLEIN; X CHROMOSOME;

EID: 0029913006     PISSN: 01418955     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01799426     Document Type: Article

References (15)

1. Antoku Y, Ohtsuka Y, Nagara H, et al (1989) A comparison of erythrocytes, lymphocytes and blood plasma as samples in fatty acid analysis for the diagnosis of adrenoleukodystrophy. J Neurol Sci 94: 193-200,
2. Aubourg P, Adamsbaum C, Lavallard-Rousseau MC, et al (1993) A two-year trial of oleic and erucic acids ('Lorenzo's oil') as treatment for adrenomyeloneuropathy. N Engl J Med 329: 745-752.
3. Böym A (1968) Separation of leukocytes from blood and bone marrow. Scand J Clin Lab Invest 21 (supplement 9): 77.
4. Koike R, Tsuji S, Ohno T, et al (1991) Physiological significance of fatty acid elongation system in adrenoleukodystrophy. J Neurol Sci 103: 188-194.
5. Korenke GC, Hunneman DH, Kohler J, et al (1995) Glyceroltrioleate/glyceroltrierucate therapy in 16 patients with X-chromosomal adrenoleukodystrophy/adrenomyeloneuropathy: effect on clinical, biochemical and neurophysiological parameters. Eur J Pediatr 154: 64-70.
6. Moser HW, Moser AB, Smith KD, et al (1992) Adrenoleukodystrophy: phenotypic variability and implications for therapy. J Inher Metab Dis 15: 645-664.
7. Muszbek L, Laposta M (1993) Covalent modification of proteins by arachidonate and eicosapentaenoate in platelets. J Biol Chem 268(24): 1843-1848.
8. Ramsey RB, Banik NL, Davison AN (1977) Galactolipid fatty acid composition in adrenoleukodystrophy (ALD). J Neurol Sci 32: 69-77.
9. Rizzo WB, Philips MW, Damman AL, et al (1987) Adrenoleukodystrophy: dietary oleic acid lowers hexacosanoate levels. Ann Neurol 21: 232-239.
10. Rizzo WB, Leshner RT, Odone A, et al (1989) Dietary erucic acid therapy for X-linked adrenoleukodystrophy. Neurology 39: 1415-1422.
11. Schutgens RBH, Bouman IW, Nijenhuis AA, et al (1993) Profiles of very-long-chain fatty acids in plasma, fibroblasts and blood cells in Zellweger syndrome, X-linked adrenoleukodystrophy, and rhizomelic chondrodysplasia punctata. Clin Chem 39: 1632-1637.
12. Suzuki S, Kobayashi T, Goto I, et al (1986) Dietary treatment of adrenoleukodystrophy. Neurology 36: 104-106.
13. Theda C, Moser AB, Powers JM, et al (1992) Phospholipids in X-linked adrenoleukodystrophy white matter: fatty acid abnormalities before the onset of demyelination. J Neurol Sci 110: 195-204.
14. Wilson R, Tocher D, Sargent JR (1992) Effects of exogenous monounsaturated fatty acids in fatty acid metabolism in cultured skin fibroblasts from adrenoleukodystrophy patients. J Neurol Sci 109: 207-214.
15. Zierz S, Schröder R, Unkrig CJ (1993) Thrombocytopenia induced by erucic acid therapy in patients with X-linked adrenoleukodystrophy. Clin Invest 71: 802-805.